首页> 美国卫生研究院文献>American Journal of Translational Research >In vitro investigation of protective mechanisms of triptolide against coronary heart disease by regulating miR-24-3p-BCL2L11 axis and PPARs-PGC1α pathway
【2h】

In vitro investigation of protective mechanisms of triptolide against coronary heart disease by regulating miR-24-3p-BCL2L11 axis and PPARs-PGC1α pathway

机译:通过调节miR-24-3P-BCL2L11轴和PPAR-PGC1α途径对冠心病抗冠心病保护机制的体外研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Coronary heart disease (CHD) is a fatal disease associated with coronary atherosclerosis. Although triptolide (TTL) has been reported to protect against CHD, the mechanism has not yet been determined. This study intended to explore its molecular regulation mechanism in CHD. It is shown in this study that TTL contributed to the proliferation and migration of in vitro cell models of CHD (endothelial cells) and the inhibition of apoptosis, and had an improvement effect on apoptosis factors and endoplasmic reticulum stress (ERS). From its mechanisms, TTL evidently downregulates miR-24-3p which is elevated in CHD, and evidently upregulates BCL2-like 11 (BCL2L11) which is suppressed in CHD, as well as affects the activation of peroxisome proliferator-activated receptors (PPARs)-Peroxisome proliferator activated receptor-γ co-activator-1α (PGC-1α) pathway of nuclear receptor transcription factors. In addition, miR-24-3p-BCL2L11-PPARs-PGC1α axis regulates protective effects of TTL against CHD.
机译:冠心病(CHD)是与冠状动脉粥样硬化相关的致命疾病。据报道雷丝酮(TTL)据报道,尚未确定该机制。该研究旨在探讨其CHD中的分子调控机制。在本研究中显示,TTL导致CHD(内皮细胞)体外细胞模型的增殖和迁移以及对细胞凋亡的抑制,对凋亡因子和内质网胁迫(ERS)的影响有所改善。从其机制,TTL明显下调MiR-24-3P,其在CHD中升高,并且明显上调在CHD中被抑制的BCL 2样11(BCL2L11),以及影响过氧化物体增殖物激活受体(PPAR)的活化 - 过氧化物体增殖剂活化受体-γ共激活剂-1α(PGC-1α)核受体转录因子的途径。此外,miR-24-3P-BCL2L11-PGC1α轴调节TTL对CHD的保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号